Paracentesis for malignant ascites is usually performed as an in-patient procedure, with a median length of stay (LoS) of 3–5 days, with intermittent clamping of the drain due to a perceived risk of ...
The conventional management of treatment-resistant, recurrent malignant ascites involves repeated large-volume paracentesis (needle drainage of fluid) procedures that are carried out in hospital. Most ...
ASCITES is a problem frequently encountered and often unsatisfactorily treated. An adjunct in the therapy of ascites has been tried in a limited number of cases and has seemed sufficiently helpful to ...
Becton, Dickinson and Company BDX, popularly known as BD, recently announced receipt of the FDA’s 510(k) clearance for its PeritX Peritoneal Catheter System. The system is to be used for the drainage ...
Ascites often develops as a complication of liver disease, causing fluid buildup in the abdominal cavity. Common treatments for ascites include reducing sodium intake, taking diuretics, and undergoing ...
Validation of urinary HE4 as a biomarker for ovarian cancer. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This abstract does not include a full text component.
FRANKLIN LAKES, N.J., June 23, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from ...
An apple a day may keep the doctor away, but an at-home catheter system from BD has the potential to keep the entire hospital away. The PeritX system allows patients with ascites to regularly drain ...
Pleural Dynamics, an early-stage medical device startup developing solutions for the management of chronic, recurrent effusions and refractory ascites, has received FDA 510(k) clearance for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results